## Sandrine Andrieu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2942133/publications.pdf

Version: 2024-02-01

257 papers

18,854 citations

59 h-index 127 g-index

270 all docs

270 docs citations

270 times ranked

21722 citing authors

#	Article	IF	Citations
1	Development and Validation of a Cutoff for the Chair Stand Test as a Screening for Mobility Impairment in the Context of the Integrated Care for Older People Program. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 104-110.	1.7	4
2	Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials. Alzheimer's and Dementia, 2022, 18, 676-687.	0.4	8
3	Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia. Alzheimer's and Dementia, 2022, 18, 2140-2150.	0.4	17
4	Plasma MCP-1 and changes on cognitive function in community-dwelling older adults. Alzheimer's Research and Therapy, 2022, 14, 5.	3.0	10
5	Sulcal morphology as cognitive decline predictor in older adults with memory complaints. Neurobiology of Aging, 2022, 113, 84-94.	1.5	1
6	Blood pressure, antihypertensive drugs, and incident frailty: The Multidomain Alzheimer Preventive Trial (MAPT). Maturitas, 2022, 162, 8-14.	1.0	7
7	Factors Predicting Engagement of Older Adults With a Coach-Supported eHealth Intervention Promoting Lifestyle Change and Associations Between Engagement and Changes in Cardiovascular and Dementia Risk: Secondary Analysis of an 18-Month Multinational Randomized Controlled Trial. Journal of Medical Internet Research, 2022, 24, e32006.	2.1	22
8	Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults. GeroScience, 2022, 44, 1489-1503.	2.1	3
9	Implementation of the WHO integrated care for older people (ICOPE) programme in clinical practice: a prospective study. The Lancet Healthy Longevity, 2022, 3, e394-e404.	2.0	37
10	Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group. The Lancet Healthy Longevity, 2022, 3, e501-e512.	2.0	26
11	Frequency of conditions associated with declines in intrinsic capacity according to a screening tool in the context of Integrated care for older people. Journal of Frailty & Dying, the, 2021, 10, 1-8.	0.8	23
12	Kidney Function and Cognitive Decline in Older Adults: Examining the Role of Neurodegeneration. Journal of the American Geriatrics Society, 2021, 69, 651-659.	1.3	12
13	What day is today? Cognitive capacity and the risk of incident dementia in the context of integrated care for older people (ICOPE Step 1). Aging Clinical and Experimental Research, 2021, 33, 3135-3139.	1.4	4
14	Visit-to-Visit Blood Pressure Variability and Incident Frailty in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1369-1375.	1.7	17
15	Development and Validation of a Model to Identify Alzheimer's Disease and Related Syndromes in Administrative Data. Current Alzheimer Research, 2021, 18, 142-156.	0.7	6
16	Prevention of dementia using mobile phone applications (PRODEMOS): protocol for an international randomised controlled trial. BMJ Open, 2021, 11, e049762.	0.8	18
17	Screening for intrinsic capacity impairments as markers of increased risk of frailty and disability in the context of integrated care for older people: Secondary analysis of MAPT. Maturitas, 2021, 150, 1-6.	1.0	30
18	Disparities in the participation and adherence of older adults in lifestyle-based multidomain dementia prevention and the motivational role of perceived disease risk and intervention benefits: an observational ancillary study to a randomised controlled trial. Alzheimer's Research and Therapy, 2021, 13, 157.	3.0	18

#	Article	IF	Citations
19	Impact of pharmacistâ€led interventions on patient care in ambulatory care settings: A systematic review. International Journal of Clinical Practice, 2021, 75, e14864.	0.8	11
20	Cross-Sectional and Longitudinal Associations Between Plasma Neurodegenerative Biomarkers and Physical Performance Among Community-Dwelling Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1874-1881.	1.7	11
21	The INSPIRE research initiative: a program for GeroScience and healthy aging research going from animal models to humans and the healthcare system. Journal of Frailty & English, the, 2021, 10, 1-8.	0.8	30
22	Framework Implementation of the INSPIRE ICOPE-CARE program in collaboration with the World Health Organization (WHO) in the Occitania region. Journal of Frailty & Digg, the, 2021, 10, 1-7.	0.8	43
23	The INSPIRE Bio-resource Research Platform for Healthy Aging and Geroscience: Focus on the Human Translational Research Cohort (The INSPIRE-T Cohort). Journal of Frailty & Ding, the, 2021, 10, 1-11.	0.8	17
24	Towards a large-scale assessment of the relationship between biological and chronological aging: The INSPIRE Mouse Cohort. Journal of Frailty & English, the, 2021, 10, 1-11.	0.8	9
25	Cognitive function and amyloid marker in frail older adults: The COGFRAIL Cohort Study. Journal of Frailty & Comp.; Aging, the, 2021, 10, 1-8.	0.8	3
26	Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-11.	1.5	3
27	When is more better? Modeling the effect of dose on the efficacy of the MAPT multidomain intervention as a function of individual characteristics. Alzheimer's and Dementia, 2021, 17, .	0.4	1
28	Design and Development of a Mobile Health (mHealth) Platform for Dementia Prevention in the Prevention of Dementia by Mobile Phone Applications (PRODEMOS) Project. Frontiers in Neurology, 2021, 12, 733878.	1.1	5
29	REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGE. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-9.	1.5	56
30	The association between apathy and frailty in older adults: a new investigation using data from the Mapt study. Aging and Mental Health, 2020, 24, 1985-1989.	1.5	8
31	Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1201-1209.	0.9	258
32	The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial. Alzheimer's Research and Therapy, 2020, 12, 134.	3.0	7
33	Dementia risk scores as surrogate outcomes for lifestyleâ€based multidomain prevention trialsâ€"rationale, preliminary evidence and challenges. Alzheimer's and Dementia, 2020, 16, 1674-1685.	0.4	18
34	Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines. Journal of Nutrition, Health and Aging, 2020, 24, 920-927.	1.5	56
35	Meal-related difficulties and weight loss in older people: Longitudinal data from MAPT study. Clinical Nutrition, 2020, 39, 3483-3488.	2.3	3
36	Pooling individual participant data from randomized controlled trials: Exploring potential loss of information. PLoS ONE, 2020, 15, e0232970.	1.1	2

#	Article	IF	Citations
37	Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial. BMC Geriatrics, 2020, 20, 99.	1.1	28
38	Worldâ€Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.4	257
39	Systematic Dementia Screening by Multidisciplinary Team Meetings in Nursing Homes for Reducing Emergency Department Transfers. JAMA Network Open, 2020, 3, e200049.	2.8	11
40	Prospective Associations Between Diffusion Tensor Imaging Parameters and Frailty in Older Adults. Journal of the American Geriatrics Society, 2020, 68, 1050-1055.	1.3	19
41	Cognitive, functional, physical, and nutritional status of the oldest old encountered in primary care: a systematic review. BMC Family Practice, 2020, 21, 58.	2.9	12
42	THE FUTURE OF ANTI-AMYLOID TRIALS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6.	1.5	34
43	CORTICAL $\hat{l}$ -AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-7.	1.5	8
44	Attitudes of at-risk older adults about prevention of cardiovascular disease and dementia using eHealth: a qualitative study in a European context. BMJ Open, 2020, 10, e037050.	0.8	4
45	Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3â€year analysis of the multidomain Alzheimer preventive trial (MAPT) study. British Journal of Clinical Pharmacology, 2019, 85, 71-99.	1.1	18
46	ANTI-TAU TRIALS FOR ALZHEIMER'S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-7.	1.5	48
47	Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohort. Neurobiology of Aging, 2019, 84, 61-69.	1.5	12
48	Effect of Long-Term Omega 3 Polyunsaturated Fatty Acid Supplementation with or without Multidomain Lifestyle Intervention on Muscle Strength in Older Adults: Secondary Analysis of the Multidomain Alzheimer Preventive Trial (MAPT). Nutrients, 2019, 11, 1931.	1.7	40
49	Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study. Journal of Nutrition, Health and Aging, 2019, 23, 805-812.	1.5	1
50	Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects. Frontiers in Neurology, 2019, 10, 989.	1.1	18
51	Associations of C-reactive protein and homocysteine concentrations with the impairment of intrinsic capacity domains over a 5-year follow-up among community-dwelling older adults at risk of cognitive decline (MAPT Study). Experimental Gerontology, 2019, 127, 110716.	1.2	39
52	Multidomain intervention and/or omegaâ€3 in nondemented elderly subjects according to amyloid status. Alzheimer's and Dementia, 2019, 15, 1392-1401.	0.4	35
53	PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	1.5	43
54	Association of 3‥ear Multidomain Intervention and Omegaâ€3 Supplementation with Frailty Incidence. Journal of the American Geriatrics Society, 2019, 67, 1700-1706.	1.3	15

#	Article	IF	CITATIONS
55	COMBINATION THERAPY FOR ALZHEIMER'S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	1.5	29
56	Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. Alzheimer's and Dementia, 2019, 15, 729-741.	0.4	68
57	Factors associated with changes of the frailty status after age 70: Findings in the MAPT study. Annals of Epidemiology, 2019, 34, 65-70.e1.	0.9	22
58	Lifestyle multidomain intervention, omega-3 supplementation, or both for reducing the risk of developing clinically relevant depressive symptoms in older adults with memory complaints? Secondary analysis from the MAPT trial. Experimental Gerontology, 2019, 120, 28-34.	1.2	5
59	Defining Vitality: Associations of Three Operational Definitions of Vitality with Disability in Instrumental Activities of Daily Living and Frailty among Elderly Over a 3-Year Follow-Up (MAPT Study). Journal of Nutrition, Health and Aging, 2019, 23, 386-392.	1.5	8
60	A bloodâ€based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 953-963.	1.8	22
61	Estimated Glomerular Filtration Rate Decline and Incident Frailty in Older Adults. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1597-1604.	2.2	14
62	Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial. The Lancet Digital Health, 2019, 1, e424-e434.	5.9	83
63	Blood pressure and cognitive performances in middle-aged adults. Journal of Hypertension, 2019, 37, 1244-1253.	0.3	15
64	Older Adults' Reasons for Participating in an eHealth Prevention Trial: A Cross-Country, Mixed-Methods Comparison. Journal of the American Medical Directors Association, 2019, 20, 843-849.e5.	1.2	28
65	Ready-meal consumption in older people: association with obesity and dietary intake. Aging Clinical and Experimental Research, 2019, 31, 855-861.	1.4	1
66	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Annals of Neurology, 2019, 85, 74-83.	2.8	18
67	TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALS. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-5.	1.5	10
68	Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. Age and Ageing, 2018, 47, 281-288.	0.7	16
69	Prospective associations between white matter hyperintensities and lower extremity function. Neurology, 2018, 90, e1291-e1297.	1.5	27
70	Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial. Journal of Alzheimer's Disease, 2018, 62, 649-663.	1,2	36
71	Diabetes Care and Dementia Among Older Adults: A Nationwide 3-Year Longitudinal Study. Journal of the American Medical Directors Association, 2018, 19, 601-606.e2.	1.2	9
72	Impact of diabetes on caregiver stress in patients with Alzheimer's disease: data from the ICTUS study. International Psychogeriatrics, 2018, 30, 1109-1117.	0.6	3

#	Article	IF	CITATIONS
73	Association Between Red Blood Cells Omega-3 Polyunsaturated Fatty Acids and White Matter Hyperintensities: The MAPT Study. Journal of Nutrition, Health and Aging, 2018, 22, 174-179.	1.5	8
74	Red blood cell membrane omega-3 fatty acid levels and physical performance: Cross-sectional data from the MAPT study. Clinical Nutrition, 2018, 37, 1141-1144.	2.3	15
<b>7</b> 5	Physical activity domains and cognitive function over three years in older adults with subjective memory complaints: Secondary analysis from the MAPT trial. Journal of Science and Medicine in Sport, 2018, 21, 52-57.	0.6	10
76	Physical Activity and Changes in White Matter Hyperintensities over Three Years. Journal of Nutrition, Health and Aging, 2018, 22, 425-430.	1.5	10
77	Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study. Value in Health, 2018, 21, 295-303.	0.1	24
78	WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE?. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-3.	1.5	22
79	FATTY ACIDS AND ALZHEIMER'S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-3.	1.5	1
80	WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-4.	1.5	7
81	A17091 Pulse wave velocity is associated with greater risk of dementia in mild cognitive impairment patients. Journal of Hypertension, 2018, 36, e340.	0.3	1
82	France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 66, 425-427.	1.2	15
83	Pulse Wave Velocity Is Associated With Greater Risk of Dementia in Mild Cognitive Impairment Patients. Hypertension, 2018, 72, 1109-1116.	1.3	37
84	Relationship Between Brain Amyloid Deposition and Instrumental Activities of Daily Living in Older Adults: A Longitudinal Study from the Multidomain Alzheimer Prevention Trial. Journal of the American Geriatrics Society, 2018, 66, 1940-1947.	1.3	9
85	Performances of Poisson–Gamma Model for Patients' Recruitment in Clinical Trials When There Are Pauses in Recruitment or When the Number of Centres is Small. Springer Proceedings in Mathematics and Statistics, 2018, , 285-299.	0.1	0
86	Simulated Clinical Trials: Principle, Good Practices, and Focus on Virtual Patients Generation. Springer Proceedings in Mathematics and Statistics, 2018, , 301-314.	0.1	1
87	Effect of Multidomain Intervention, Omega-3 Polyunsaturated Fatty Acids Supplementation or their Combinaison on Cognitive Function in Non-Demented Older Adults According to Frail Status: Results from the MAPT Study. Journal of Nutrition, Health and Aging, 2018, 22, 923-927.	1.5	19
88	Effects of a 3-Year Multi-Domain Intervention with or without Omega-3 Supplementation on Cognitive Functions in Older Subjects with Increased CAIDE Dementia Scores. Journal of Alzheimer's Disease, 2018, 64, 71-78.	1.2	49
89	Impact of collaborative pharmaceutical care on in-patients' medication safety: study protocol for a stepped wedge cluster randomized trial (MEDREV study). Trials, 2018, 19, 19.	0.7	13
90	Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?. Journal of Nutrition, Health and Aging, 2018, 22, 982-988.	1.5	13

#	Article	IF	CITATIONS
91	The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies―(SPRINTT) randomized controlled trial: design and methods. Aging Clinical and Experimental Research, 2017, 29, 89-100.	1.4	131
92	Determinants of Dropout and Nonadherence in a Dementia Prevention Randomized Controlled Trial: The Prevention of Dementia by Intensive Vascular Care Trial. Journal of the American Geriatrics Society, 2017, 65, 1505-1513.	1.3	20
93	Reversible states of physical and/or cognitive dysfunction: A 9-year longitudinal study. Journal of Nutrition, Health and Aging, 2017, 21, 271-275.	1.5	11
94	Effect of dementia on receipt of influenza vaccine: a cohort study in French older adults using administrative data: 2007–2012. Fundamental and Clinical Pharmacology, 2017, 31, 471-480.	1.0	5
95	On the Fleming–Harrington test for late effects in prevention randomized controlled trials. Journal of Statistical Theory and Practice, 2017, 11, 418-435.	0.3	8
96	Crossâ $\in$ sectional associations of cortical $\hat{l}^2$ â $\in$ amyloid with erythrocyte membrane longâ $\in$ chain polyunsaturated fatty acids in older adults with subjective memory complaints. Journal of Neurochemistry, 2017, 142, 589-596.	2.1	10
97	Using Poisson–gamma model to evaluate the duration of recruitment process when historical trials are available. Statistics in Medicine, 2017, 36, 3605-3620.	0.8	9
98	How to deal with the Poisson-gamma model to forecast patients' recruitment in clinical trials when there are pauses in recruitment dynamic?. Contemporary Clinical Trials Communications, 2017, 5, 144-152.	0.5	8
99	Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurology, The, 2017, 16, 377-389.	4.9	576
100	Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study. Journal of Alzheimer's Disease, 2017, 58, 87-97.	1.2	4
101	Cognitive changes with omega-3 polyunsaturated fatty acids in non-demented older adults with low omega-3 index. Journal of Nutrition, Health and Aging, 2017, 21, 988-993.	1.5	45
102	Cross-sectional associations of total plasma homocysteine with cortical $\hat{l}^2$ -amyloid independently and as a function of omega 3 polyunsaturated fatty acid status in older adults at risk of dementia. Journal of Nutrition, Health and Aging, 2017, 21, 1075-1080.	1.5	14
103	Association of cortical $\hat{l}^2$ -amyloid with erythrocyte membrane monounsaturated and saturated fatty acids in older adults at risk of dementia. Journal of Nutrition, Health and Aging, 2017, 21, 1170-1175.	1.5	4
104	Lessons from the Multidomain Alzheimer Preventive Trial – Authors' reply. Lancet Neurology, The, 2017, 16, 586.	4.9	2
105	Associations between white matter hyperintensities and cognitive decline over three years in non-dementia older adults with memory complaints. Journal of the Neurological Sciences, 2017, 379, 266-270.	0.3	13
106	Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. Journal of Alzheimer's Disease, 2017, 60, 1567-1578.	1.2	15
107	Collaborative efforts to prevent Alzheimer's disease. Journal of Nutrition, Health and Aging, 2017, 21, 1072-1074.	1.5	1
108	Physical Activity and Incident Chronic Diseases: A Longitudinal Observational Study in 16 European Countries. American Journal of Preventive Medicine, 2017, 52, 373-378.	1.6	58

#	Article	IF	CITATIONS
109	Development and Validation of an Interactive Internet Platform for Older People: The Healthy Ageing Through Internet Counselling in the Elderly Study. Telemedicine Journal and E-Health, 2017, 23, 96-104.	1.6	36
110	Cross-Sectional and Prospective Associations Between Î <sup>2</sup> -Amyloid in the Brain and Chair Rise Performance in Nondementia Older Adults With Spontaneous Memory Complaints. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 278-283.	1.7	9
111	Cross-sectional Associations of Fatigue with Cerebral $\hat{l}^2$ -Amyloid in Older Adults at Risk of Dementia. Frontiers in Medicine, 2017, 4, 173.	1.2	9
112	Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. Frontiers in Aging Neuroscience, 2017, 9, 312.	1.7	26
113	Improving data sharing in research with context-free encoded missing data. PLoS ONE, 2017, 12, e0182362.	1.1	3
114	EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER'S PREVENTION TRIALS. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-9.	1.5	18
115	Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer's Disease. Current Alzheimer Research, 2017, 14, 255-267.	0.7	2
116	THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER'S DISEASE. STRATEGY, METHODS AND INITIAL RESULTS. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-11.	1.5	3
117	How Older Persons Perceive the Loss of Independence: The Need of a Holistic Approach to Frailty. Journal of Frailty & Dournal of Frailt	0.8	7
118	kmlShape: An Efficient Method to Cluster Longitudinal Data (Time-Series) According to Their Shapes. PLoS ONE, 2016, 11, e0150738.	1.1	69
119	Frailty Index and Cognitive Decline in Alzheimer's Disease: Data from the Impact of Cholinergic Treatment <scp>US</scp> e Study. Journal of the American Geriatrics Society, 2016, 64, 1165-1170.	1.3	30
120	Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. BMJ Open, 2016, 6, e010806.	0.8	75
121	Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. International Psychogeriatrics, 2016, 28, 707-717.	0.6	96
122	Refining Mild-to-Moderate Alzheimer Disease Screening: A Tool for Clinicians. Journal of the American Medical Directors Association, 2016, 17, 913-920.	1.2	3
123	Physical Activity and Cognitive Function in Middle-Aged and Older Adults. Mayo Clinic Proceedings, 2016, 91, 1515-1524.	1.4	45
124	Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5â€year GuidAge Alzheimer's prevention trial. Alzheimer's and Dementia, 2016, 12, 1216-1225.	0.4	23
125	Caloric restriction and aerobic exercise in sarcopenic and nonâ€sarcopenic obese women: an observational and retrospective study. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 284-289.	2.9	22
126	Clinical research for older adults in rural areas: the MINDED study experience. Age, 2016, 38, 30.	3.0	7

#	Article	IF	CITATIONS
127	Dementia beyond 2025: Knowledge and uncertainties. Dementia, 2016, 15, 6-21.	1.0	48
128	Assessing Alzheimer's disease patients' quality of life: Discrepancies between patient and caregiver perspectives. Alzheimer's and Dementia, 2016, 12, 427-437.	0.4	31
129	Relationship of regional brain $\hat{l}^2$ -amyloid to gait speed. Neurology, 2016, 86, 36-43.	1.5	119
130	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318
131	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	4.9	1,242
132	Brain Amyloid Deposition Is Associated With Lower Instrumental Activities of Daily Living Abilities in Older Adults. Results From the MAPT Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 391-397.	1.7	19
133	Frailty Index and Incident Mortality, Hospitalization, and Institutionalization in Alzheimer's Disease: Data From the ICTUS Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 543-548.	1.7	34
134	Web-Based Interventions Targeting Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2016, 18, e55.	2.1	116
135	Physical Activity and Amyloidâ€∢i>β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2015, 63, 1634-1639.	1.3	35
136	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. Journal of Alzheimer's Disease, 2015, 48, 793-804.	1.2	28
137	A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort. Journal of the American Medical Directors Association, 2015, 16, 1104.e1-1104.e7.	1.2	12
138	Analysing time to event data in dementia prevention trials: The example of the guidage study of EGB761A®. Journal of Nutrition, Health and Aging, 2015, 19, 1009-1011.	1.5	13
139	Dementia Diagnosis and Influenza Vaccination in French Nursing Home Residents. Journal of the American Geriatrics Society, 2015, 63, 1256-1258.	1.3	3
140	An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials. Statistics in Medicine, 2015, 34, 541-557.	0.8	16
141	Nutrition and Cognition in Aging Adults. Clinics in Geriatric Medicine, 2015, 31, 453-464.	1.0	22
142	Preventable latrogenic Disability in Elderly Patients During Hospitalization. Journal of the American Medical Directors Association, 2015, 16, 674-681.	1.2	111
143	Evolution of General Practitioners' Preferences for Antipsychotics in France, 2003–2010. Psychiatric Services, 2015, 66, 434-437.	1.1	0
144	Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms. CNS Drugs, 2015, 29, 113-130.	2.7	177

#	Article	IF	CITATIONS
145	Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. International Psychogeriatrics, 2015, 27, 181-197.	0.6	29
146	Prevention Studies in Alzheimer's Disease: Progress Towards the Development of New Therapeutics. CNS Drugs, 2015, 29, 519-528.	2.7	7
147	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurology, The, 2015, 14, 926-944.	4.9	227
148	Living Alone with Alzheimer's Disease and the Risk of Adverse Outcomes: Results from the Plan de Soin et d'Aide dans la maladie d'Alzheimer Study. Journal of the American Geriatrics Society, 2015, 63, 651-658.	1.3	18
149	Understanding the Complexities of Functional Ability in Alzheimer's Disease: More Than Just Basic and Instrumental Factors. Current Alzheimer Research, 2014, 11, 357-366.	0.7	20
150	Normalized Mini-Mental State Examination for Assessing Cognitive Change in Population-Based Brain Aging Studies. Neuroepidemiology, 2014, 43, 15-25.	1.1	58
151	Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. Frontiers in Aging Neuroscience, 2014, 6, 54.	1.7	155
152	P3-341: MANAGEMENT OF VASCULAR AND LIFESTYLE-RELATED RISK FACTORS FOR ALZHEIMER'S DISEASE AND DEMENTIA IN OLDER ADULTS: A EUROPEAN PERSPECTIVE. , 2014, 10, P754-P755.		4
153	Sexually dimorphic patterns of nutritional intake and eating behaviors in community-dwelling older adults with normal and slow gait speed. Journal of Nutrition, Health and Aging, 2014, 18, 228-233.	1.5	22
154	A 2-Year Prospective Cohort Study of Antidementia Drug Non-Persistency in Mild-to-Moderate Alzheimer's Disease in Europe. CNS Drugs, 2014, 28, 157-170.	2.7	20
155	Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. European Neuropsychopharmacology, 2014, 24, 95-104.	0.3	76
156	Description of 1,108 older patients referred by their physician to the "Geriatric Frailty Clinic (G.F.C) for assessment of frailty and prevention of disability―at the gerontopole. Journal of Nutrition, Health and Aging, 2014, 18, 457-464.	1.5	102
157	The Multidomain Intervention to preveNt Disability in ElDers (MINDED) project: Rationale and study design of a pilot study. Contemporary Clinical Trials, 2014, 38, 145-154.	0.8	25
158	A comparison of the constant piecewise weighted logrank and Fleming-Harrington tests. Electronic Journal of Statistics, 2014, 8, .	0.4	10
159	A Self-Reported Screening Tool for Detecting Community-Dwelling Older Persons with Frailty Syndrome in the Absence of Mobility Disability: The FiND Questionnaire. PLoS ONE, 2014, 9, e101745.	1.1	77
160	Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making. journal of prevention of Alzheimer's disease, The, 2014, 1, 117-123.	1.5	9
161	Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!. European Journal of Clinical Pharmacology, 2013, 69, 1589-1597.	0.8	68
162	How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: A statement from the international academy on nutrition and aging task force. Journal of Nutrition, Health and Aging, 2013, 17, 619-623.	1.5	11

#	Article	IF	Citations
163	Promoting access to innovation for frail old persons. Journal of Nutrition, Health and Aging, 2013, 17, 688-693.	1.5	55
164	Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD expert meeting. Journal of Nutrition, Health and Aging, 2013, 17, 653-660.	1.5	43
165	Persistent use of Analgesic Medications in Mild-to-Moderate Alzheimer's Disease. Drugs and Aging, 2013, 30, 439-445.	1.3	9
166	Cognitive frailty: Rational and definition from an (I.A.N.A./I.A.G.G.) International Consensus Group. Journal of Nutrition, Health and Aging, 2013, 17, 726-734.	1.5	659
167	Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2013, 9, S45-55.	0.4	96
168	Early prediction of failure to lose weight after obesity surgery. Surgery for Obesity and Related Diseases, 2013, 9, 118-121.	1.0	30
169	Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study. Journal of Neurology, 2013, 260, 1859-1865.	1.8	35
170	Relationship Between Markers of Insulin Resistance, Markers of Adiposity, HbA1c, and Cognitive Functions in a Middle-Aged Population–Based Sample: the MONA LISA Study. Diabetes Care, 2013, 36, 1512-1521.	4.3	50
171	The cognitive impairment of frail older persons. Journal of Nutrition, Health and Aging, 2013, 17, 735-737.	1.5	12
172	Comparison of Informal Care Time and Costs in Different Age-Related Dementias: A Review. BioMed Research International, 2013, 2013, 1-15.	0.9	39
173	Weight changes in Alzheimer's disease patients with increased aberrant motor behavior. International Journal of Geriatric Psychiatry, 2013, 28, 998-1004.	1.3	6
174	Gait Speed, Body Composition, and Dementia. The EPIDOS-Toulouse Cohort. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67A, 425-432.	1.7	80
175	Falls and Risk Factors for Falls in Community-Dwelling Adults With Dementia (NutriAlz Trial). Alzheimer Disease and Associated Disorders, 2012, 26, 74-80.	0.6	35
176	Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. Current Alzheimer Research, 2012, 9, 902-912.	0.7	42
177	Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer's Disease Patients: Evidence for a Role of Dementia Severity. Current Alzheimer Research, 2012, 9, 1106-1116.	0.7	32
178	Psychotropic Drug Consumption at Admission and Discharge of Nursing Home Residents. Journal of the American Medical Directors Association, 2012, 13, 407.e7-407.e12.	1,2	38
179	PND24 Methodological Considerations in Cost of Illness Studies on Alzheimer Disease. Value in Health, 2012, 15, A550.	0.1	0
180	Weight Loss and Rapid Cognitive Decline in Community-Dwelling Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 647-654.	1.2	113

#	Article	IF	Citations
181	Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurology, The, 2012, 11, 851-859.	4.9	331
182	Methodological challenges in designing dementia prevention trials â€" The European Dementia Prevention Initiative (EDPI). Journal of the Neurological Sciences, 2012, 322, 64-70.	0.3	96
183	Exploring the Relationship between Alzheimer's Disease Severity and Longitudinal Costs. Value in Health, 2012, 15, 412-419.	0.1	46
184	Improving Care of Older Adults With Dementia: Description of 6299 Hospitalizations over 11 Years in a Special Acute Care Unit. Journal of the American Medical Directors Association, 2012, 13, 486.e1-486.e6.	1.2	28
185	Methodological considerations in cost of illness studies on Alzheimer disease. Health Economics Review, 2012, 2, 18.	0.8	62
186	Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort. Journal of Nutrition, Health and Aging, 2012, 16, 134-137.	1.5	58
187	Alzheimer's disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology. Journal of Nutrition, Health and Aging, 2012, 16, 339-345.	1.5	38
188	Representations and practices of prevention in elderly populations: Investigating acceptance to participate in and adhesion to an intervention study for the prevention of Alzheimer's disease (accept) Tj ETQq0 352-354.	0 Q.ggBT /	Overlock 10 <sup>-</sup>
189	Recruitment strategies for preventive trials. The MAPT study (Multidomain Alzheimer Preventive Trial). Journal of Nutrition, Health and Aging, 2012, 16, 355-359.	1.5	61
190	Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. The Real.FR cohort. Diabetic Medicine, 2012, 29, 541-548.	1.2	17
191	Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. Journal of the American Medical Directors Association, 2011, 12, 249-256.	1.2	2,427
192	International Association of Gerontology and Geriatrics: A Global Agenda for Clinical Research and Quality of Care in Nursing Homes. Journal of the American Medical Directors Association, 2011, 12, 184-189.	1.2	215
193	Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 2011, 95, 579-593.	2.8	119
194	Prevention trials in Alzheimer's disease: An EU-US task force report. Progress in Neurobiology, 2011, 95, 594-600.	2.8	62
195	AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2011, 7, e109-17.	0.4	17
196	Suitability of the Clinical Dementia Rating‧um of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimer's and Dementia, 2011, 7, 602.	0.4	79
197	Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010., 2011, 7, 127-132.		35
198	Longâ€term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimer's and Dementia, 2011, 7, 579-592.	0.4	60

#	Article	IF	Citations
199	Informal Caregiving and Self-Reported Mental and Physical Health: Results From the Gazel Cohort Study. American Journal of Public Health, 2011, 101, 1971-1979.	1.5	71
200	Public financial support receipt and non-medical resource utilization in Alzheimer's disease results from the PLASA study. Social Science and Medicine, 2011, 72, 1310-1316.	1.8	31
201	Incidence and predictive factors of depressive symptoms in Alzheimer's disease: The REAL.FR study. Journal of Nutrition, Health and Aging, 2011, 15, 609-617.	1.5	30
202	Health and nutrition promotion program for patients with dementia (NutriAlz): Cluster randomized trial. Journal of Nutrition, Health and Aging, 2011, 15, 822-830.	1.5	74
203	How Should We Deal with Missing Data in Clinical Trials Involving Alzheimers Disease Patients?. Current Alzheimer Research, 2011, 8, 421-433.	0.7	26
204	Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort. International Psychogeriatrics, 2010, 22, 120-128.	0.6	25
205	Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). BMJ: British Medical Journal, 2010, 340, c2466-c2466.	2.4	48
206	The primary care physician and Alzheimer's disease: An international position paper. Journal of Nutrition, Health and Aging, 2010, 14, 110-120.	1.5	83
207	Predictive factors of hospitalizations in Alzheimer's disease: A two-year prospective study in 686 patients of the REAL.FR study. Journal of Nutrition, Health and Aging, 2010, 14, 288-291.	1.5	38
208	Differences in resource use and costs of dementia care between European countries: Baseline data from the ictus study. Journal of Nutrition, Health and Aging, 2010, 14, 648-654.	1.5	79
209	Regional Variation on the Presentation of Alzheimer's Disease Patients in Memory Clinics within Europe: Data from the ICTUS Study. Journal of Alzheimer's Disease, 2010, 21, 155-165.	1.2	10
210	Predictive Factors of Discontinuation and Switch of Cholinesterase Inhibitors in Community-Dwelling Patients with Alzheimer's Disease. CNS Drugs, 2010, 24, 431-442.	2.7	29
211	Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia. Journal of Alzheimer's Disease, 2009, 16, 235-270.	1.2	42
212	An Abnormal "One-leg Balance―Test Predicts Cognitive Decline During Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 525-531.	1.2	38
213	Cardiovascular Disease Risk Factors and Progression of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2009, 27, 240-246.	0.7	26
214	Characteristics of Alzheimer's disease patients with a rapid weight loss during a six-year follow-up. Clinical Nutrition, 2009, 28, 141-146.	2.3	45
215	Nutritional assessment of residents in Long-Term Care Facilities (LTCFS): Recommendations of the task force on nutrition and ageing of the IAGG European Region and the IANA. Journal of Nutrition, Health and Aging, 2009, 13, 475-483.	1.5	90
216	Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. Journal of Nutrition, Health and Aging, 2009, 13, 881-889.	1.5	1,487

#	Article	IF	CITATIONS
217	Descriptive analysis of hospitalizations of patients with Alzheimer's disease: A two-year prospective study of 686 patients from the REAL.FR study. Journal of Nutrition, Health and Aging, 2009, 13, 890-892.	1.5	23
218	Biomarkers in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 119-124.	1.8	26
219	Spared and Impaired Abilities in Community-Dwelling Patients Entering the Severe Stage of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2009, 28, 412-417.	0.7	30
220	Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.―The Multidomain Alzheimer Preventive Trial (MAPT): A new approach to the prevention of Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 114-121.	0.4	90
221	Does Cognitive Impairment Influence Burden in Caregivers of Patients with Alzheimer's Disease?. Journal of Alzheimer's Disease, 2009, 17, 105-114.	1.2	88
222	Special acute care unit for older adults with Alzheimer's disease. International Journal of Geriatric Psychiatry, 2008, 23, 215-219.	1.3	20
223	A 2â€year followâ€up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort). International Journal of Geriatric Psychiatry, 2008, 23, 460-465.	1.3	17
224	The prevalence of clinically significant depressive symptoms in Alzheimer's disease: relationship with other psychological and behavioural symptoms. International Journal of Geriatric Psychiatry, 2008, 23, 1209-1211.	1.3	7
225	Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurology, The, 2008, 7, 436-450.	4.9	146
226	Prognosis of Alzheimer's disease today: A twoâ€year prospective study in 686 patients from the REALâ€FR Study. Alzheimer's and Dementia, 2008, 4, 22-29.	0.4	84
227	Memory health clinics—a first step to prevention. Alzheimer's and Dementia, 2008, 4, S144-9.	0.4	5
228	Dementia Prevention: Methodological Explanations for Inconsistent Results. Epidemiologic Reviews, 2008, 30, 35-66.	1.3	145
229	Predictive Factors of Attrition in a Cohort of Alzheimer Disease Patients. Neuroepidemiology, 2008, 31, 69-79.	1.1	47
230	GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimers Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data. Current Alzheimer Research, 2008, 5, 406-415.	0.7	47
231	Disease Modifying Trials in Alzheimer's Disease: Perspectives for the Future. Journal of Alzheimer's Disease, 2008, 15, 289-301.	1.2	15
232	Predictive Value of Rapid Decline in Mini Mental State Examination in Clinical Practice for Prognosis in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 109-116.	0.7	44
233	The ICTUS Study: A Prospective Longitudinal Observational Study of 1,380 AD Patients in Europe. Neuroepidemiology, 2007, 29, 29-38.	1.1	51
234	RESPONSE TO LETTER FROM GARCIA AND COLLEAGUES ON CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 679-680.	1.7	1

#	Article	IF	Citations
235	Predictive Value of 6-Month Decline in ADAS-cog for Survival without Severe Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2007, 23, 168-174.	0.7	14
236	Wandering Behavior and Alzheimer Disease. The REAL.FR Prospective Study. Alzheimer Disease and Associated Disorders, 2007, 21, 31-38.	0.6	50
237	New assessment of dependency in demented patients: Impact on the quality of life in informal caregivers. Psychiatry and Clinical Neurosciences, 2007, 61, 234-242.	1.0	27
238	Exercise Program for Nursing Home Residents with Alzheimer's Disease: A 1-Year Randomized, Controlled Trial. Journal of the American Geriatrics Society, 2007, 55, 158-165.	1.3	554
239	Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurology, The, 2007, 6, 56-62.	4.9	142
240	Outcome of Alzheimer's Disease: Potential Impact of Cholinesterase Inhibitors. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 516-520.	1.7	35
241	Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients. American Journal of Clinical Nutrition, 2005, 82, 435-441.	2.2	96
242	Cognitive impairment and composition of drinking water in women: findings of the EPIDOS Study. American Journal of Clinical Nutrition, 2005, 81, 897-902.	2.2	59
243	Beyond the global score of the Zarit Burden Interview: useful dimensions for clinicians. International Journal of Geriatric Psychiatry, 2005, 20, 254-260.	1.3	161
244	Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients. American Journal of Clinical Nutrition, 2005, 82, 435-441.	2.2	96
245	Minimum Data Set for Nutritional Intervention Studies in Elderly People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2004, 59, M724-M729.	1.7	14
246	Improvement of Weight and Fat-Free Mass with Oral Nutritional Supplementation in Patients with Alzheimer's Disease at Risk of Malnutrition: A Prospective Randomized Study. Journal of the American Geriatrics Society, 2004, 52, 1702-1707.	1.3	146
247	Body composition in French women 75+ years of age: The EPIDOS study. Mechanisms of Ageing and Development, 2003, 124, 311-316.	2.2	64
248	Comparison of bone mineral density and body composition measurements in women obtained from two DXA instruments. Mechanisms of Ageing and Development, 2003, 124, 317-321.	2.2	30
249	Association of Alzheimer's Disease Onset With Ginkgo Biloba and Other Symptomatic Cognitive Treatments in a Population of Women Aged 75 Years and Older From the EPIDOS Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M372-M377.	1.7	<b>7</b> 3
250	Music Perception in Adult Cochlear Implant Recipients. Acta Oto-Laryngologica, 2003, 123, 826-835.	0.3	155
251	Predictive factors of acute hospitalization in 134 patients with Alzheimer's disease: a one year prospective study. International Journal of Geriatric Psychiatry, 2002, 17, 422-426.	1.3	55
252	Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2002, 17, 950-955.	1.3	67

#	Article	IF	CITATIONS
253	Is There a Relationship Between Fat-Free Soft Tissue Mass and Low Cognitive Function? Results From a Study of 7,105 Women. Journal of the American Geriatrics Society, 2002, 50, 1796-1801.	1.3	128
254	Nutrition assessment in the elderly. Current Opinion in Clinical Nutrition and Metabolic Care, 2001, 4, 5-8.	1.3	90
255	Instrumental Activities of Daily Living as a Potential Marker of Frailty: A Study of 7364 Community-Dwelling Elderly Women (the EPIDOS Study). Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2001, 56, M448-M453.	1.7	176
256	Weight loss in Alzheimer disease. American Journal of Clinical Nutrition, 2000, 71, 637S-642S.	2.2	205
257	Alzheimer disease: protective factors. American Journal of Clinical Nutrition, 2000, 71, 643S-649S.	2.2	94